文献速递药物不良反应与药物警戒特殊人群用药药物相互作用

儿童与成人心包炎的当前药物治疗管理:改善预后的展望

Current pharmacotherapy management of children and adults with pericarditis: Prospectus for improved outcomes.
PubMed 文献 · Pharmacotherapy · 2021-12-06

心包炎是儿童和成人最常见的炎症性心包疾病。自2015年ESC指南发布以来,药物治疗管理有重要更新。本文综述了抗炎治疗、秋水仙碱和免疫治疗在特发性心包炎和心脏损伤后综合征中的应用,强调高剂量抗炎治疗控制症状但不改善炎症过程,秋水仙碱作为辅助治疗降低复发风险,全身糖皮质激素增加复发风险并保留为二线治疗,免疫治疗为三线。药物警戒策略如C反应蛋白和不良事件监测对平衡疗效与安全性很重要。

要点

  • 高剂量抗炎治疗用于控制儿童和成人心包炎症状,但不改善炎症过程。
  • 秋水仙碱作为辅助治疗可降低特发性心包炎复发风险、减轻症状。
  • 全身糖皮质激素增加特发性心包炎复发风险,保留为二线治疗。

核心结论

  • 高剂量抗炎治疗应控制儿童和成人心包炎症状,但不改善炎症过程。
  • 秋水仙碱作为辅助治疗可降低特发性心包炎复发风险、减轻症状、改善发病率。
  • 全身糖皮质激素增加特发性心包炎复发风险,保留为二线治疗,心脏损伤后综合征一般避免使用。
  • 免疫治疗为复发性特发性心包炎三线治疗,心脏损伤后综合征证据有限。

研究设计与样本

  • 综述性文章,总结儿童和成人心包炎的当前药物治疗管理。

主要发现

  • 抗炎药物选择应基于药物相互作用、疾病相互作用、成本、耐受性和患者年龄,并在数周至数月内逐渐减量。
  • 秋水仙碱在特发性心包炎和心脏损伤后综合征中均可考虑作为辅助治疗。
  • 免疫治疗在心脏损伤后综合征中的证据有限。
  • 药物警戒策略如C反应蛋白和不良事件监测有助于平衡疗效与安全性。

关键数值与推荐

  • 高剂量抗炎治疗用于控制症状,但不改善炎症过程。
  • 秋水仙碱作为辅助治疗可降低复发风险、减轻症状。
  • 全身糖皮质激素增加复发风险,保留为二线治疗。
  • 免疫治疗为三线治疗。

临床怎么用

  • 根据药物相互作用、疾病相互作用、成本、耐受性和患者年龄选择抗炎药物,并逐渐减量。
  • 在特发性心包炎和心脏损伤后综合征中考虑加用秋水仙碱作为辅助治疗。
  • 避免在心脏损伤后综合征中使用全身糖皮质激素。
  • 使用C反应蛋白和不良事件监测进行药物警戒。

局限性

  • 数据质量因心脏损伤后综合征或特发性病因以及成人和儿童人群而异。
  • 免疫治疗在心脏损伤后综合征中的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pericarditis is the most common inflammatory pericardial disease in both children and adults. Since the 2015 European Society of Cardiology Guidelines for the diagnosis and management of pericardial disease were published, there have been significant updates to management. Pharmacotherapy has been historically reserved for idiopathic pericarditis (IP). However, there has been increasing use of pharmacotherapies, such as anti-inflammatory therapies, colchicine, and immunotherapies for other causes of pericarditis, such as post-cardiac injury syndromes (PCIS). Nevertheless, the quality of data varies depending on PCIS or idiopathic etiologies, as well as the adult and pediatric population. High-dose anti-inflammatory therapies should be used to manage symptoms associated with either etiology of pericarditis in both adults and children, but do not ameliorate the inflammatory disease process. Choice of anti-inflammatory should be guided by drug-drug/disease interactions, cost, tolerability, patient age, and should be tapered accordingly over several weeks to months. Colchicine should be added as adjuvant therapy to anti-inflammatory therapies in adults and children with IP, as it has been shown to lower the risk of recurrence, reduce pericarditis symptoms, and improve morbidity. Colchicine is also reasonable to add to adults and children with pericarditis secondary to PCIS. Systemic glucocorticoids increase risk of recurrence in adults and children with IP and are reserved for second-line treatment in acute and recurrent IP; they are generally avoided in PCIS. Immunotherapies are regarded as third-line for recurrent IP in adults and children. Limited evidence exists to support their use in patients with pericarditis from PCIS. Pharmacovigilance strategies, such as C-reactive protein and adverse drug event monitoring, are also important toward balancing efficacy and safety of the various strategies used to manage pericarditis in adults and children.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Schwier NC, Tsui J, Perrine JA, et al. Current pharmacotherapy management of children and adults with pericarditis: Prospectus for improved outcomes. Pharmacotherapy. 2021. PMID: 34669979. doi:10.1002/phar.2640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。